Lipella Pharmaceuticals (Lipella Pharmaceuticals) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals COGS-to-Revenue?

Lipella Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.84 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Lipella Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lipella Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 was %.

Lipella Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Lipella Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals COGS-to-Revenue Chart

Lipella Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

1.01

5.62

13.85

6.75

Lipella Pharmaceuticals Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial									-	-	-	1.01	-

Lipella Pharmaceuticals COGS-to-Revenue Calculation

Lipella Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.039	/	0.45
	=	6.75

Lipella Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.843	/	0
	=

Lipella Pharmaceuticals (NAS:LIPO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lipella Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.843 / 0
	=	%

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Lipella Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208

Website

https://www.lipella.com

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.

Executives

Lori Birder	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman	director, 10 percent owner, officer: See Remarks	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston	officer: Chief Financial Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor	director, 10 percent owner, officer: Chief Medical Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208